ENvue Medical filed an 8-K on January 30, 2026 disclosing amendments to its Series H Convertible Preferred Stock that remove all downside protection for common shareholders.
What Changed
The company amended the Series H conversion terms to eliminate the floor price. Under the new structure, the conversion price equals 85% of the average of the three lowest VWAPs over the preceding 10 trading days, with no minimum price.
In exchange for removing this structural protection, preferred holders agreed to inject $2.5 million in new capital.
Death Spiral Structure
The filing reveals a classic death spiral mechanism:
- Preferred converts at 85% of recent trading lows
- Conversion creates selling pressure, pushing the stock lower
- Next conversion occurs at an even lower price (no floor to halt the decline)
- Full ratchet anti-dilution provisions (Section 7(b), lines 217-243) automatically adjust the conversion price downward if the company issues equity at lower prices
The original floor price was the only protection preventing unlimited dilution. Its removal leaves common shareholders exposed to uncapped conversion risk.
Market Reaction and Context
The stock fell 15.9% on the filing date, trading at $3.23—down 95% over the prior year and near the bottom of its 52-week range ($0.99 - $162.50). Volume spiked to 191.9× the weekly average.
Distressed Financing Signal
The $2.5 million raise amount is immaterial relative to the structural concession. Companies with access to capital on reasonable terms do not eliminate all downside protection for such a small cash infusion. This is what pre-insolvency financing looks like.
The filing provides strong evidence (likelihood ratio 0.2) that ENvue is in severe financial distress with limited financing alternatives.
// comments (0)